CR11319A - Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica - Google Patents

Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica

Info

Publication number
CR11319A
CR11319A CR11319A CR11319A CR11319A CR 11319 A CR11319 A CR 11319A CR 11319 A CR11319 A CR 11319A CR 11319 A CR11319 A CR 11319A CR 11319 A CR11319 A CR 11319A
Authority
CR
Costa Rica
Prior art keywords
stromatic
proteins
antigen
lymphopoyetin
capaces
Prior art date
Application number
CR11319A
Other languages
English (en)
Spanish (es)
Inventor
Michael R Comeau
James F Smothers
Bo-Rin P Yoon
Christopher Mehlin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11319(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR11319A publication Critical patent/CR11319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR11319A 2007-09-10 2010-03-17 Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica CR11319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25

Publications (1)

Publication Number Publication Date
CR11319A true CR11319A (es) 2010-04-21

Family

ID=40242598

Family Applications (2)

Application Number Title Priority Date Filing Date
CR11319A CR11319A (es) 2007-09-10 2010-03-17 Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica
CR20150095A CR20150095A (es) 2007-09-10 2015-02-24 Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20150095A CR20150095A (es) 2007-09-10 2015-02-24 Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica

Country Status (36)

Country Link
US (6) US7982016B2 (cg-RX-API-DMAC7.html)
EP (3) EP3524622A1 (cg-RX-API-DMAC7.html)
JP (8) JP5956716B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140141666A (cg-RX-API-DMAC7.html)
CN (2) CN101809035B (cg-RX-API-DMAC7.html)
AR (1) AR068508A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008300028B2 (cg-RX-API-DMAC7.html)
CA (1) CA2698382C (cg-RX-API-DMAC7.html)
CL (2) CL2008002668A1 (cg-RX-API-DMAC7.html)
CR (2) CR11319A (cg-RX-API-DMAC7.html)
CY (2) CY1117702T1 (cg-RX-API-DMAC7.html)
DK (1) DK2205635T3 (cg-RX-API-DMAC7.html)
EA (2) EA201590631A1 (cg-RX-API-DMAC7.html)
ES (1) ES2581229T3 (cg-RX-API-DMAC7.html)
FR (1) FR22C1059I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20160638T1 (cg-RX-API-DMAC7.html)
HU (2) HUE028361T2 (cg-RX-API-DMAC7.html)
IL (3) IL204069A (cg-RX-API-DMAC7.html)
JO (1) JO3351B1 (cg-RX-API-DMAC7.html)
LT (2) LT2205635T (cg-RX-API-DMAC7.html)
LU (1) LUC00289I2 (cg-RX-API-DMAC7.html)
MX (1) MX2010002590A (cg-RX-API-DMAC7.html)
MY (1) MY150242A (cg-RX-API-DMAC7.html)
NL (1) NL301207I2 (cg-RX-API-DMAC7.html)
NO (1) NO2022055I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ583933A (cg-RX-API-DMAC7.html)
PE (2) PE20110668A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501025B1 (cg-RX-API-DMAC7.html)
PL (1) PL2205635T3 (cg-RX-API-DMAC7.html)
PT (1) PT2205635T (cg-RX-API-DMAC7.html)
RS (1) RS54950B1 (cg-RX-API-DMAC7.html)
SG (2) SG178781A1 (cg-RX-API-DMAC7.html)
SI (1) SI2205635T1 (cg-RX-API-DMAC7.html)
TW (2) TWI449709B (cg-RX-API-DMAC7.html)
WO (1) WO2009035577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001895B (cg-RX-API-DMAC7.html)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
EP3594356A1 (en) * 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AU2011305306C1 (en) * 2010-09-22 2016-02-18 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2013067051A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Biomarkers for tslp treatment
KR20180137614A (ko) * 2012-04-27 2018-12-27 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
KR20170016335A (ko) 2014-06-03 2017-02-13 암겐 인코포레이티드 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
MX392725B (es) 2014-10-14 2025-03-24 Amgen Inc Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
UY36578A (es) * 2015-03-11 2016-09-30 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
UY36889A (es) * 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
US11001624B2 (en) * 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
TWI802193B (zh) 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10919966B2 (en) * 2016-08-05 2021-02-16 Y-Biologics Inc. Antibody to programmed death-ligand 1 (PD-L1) and use thereof
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
PL3383916T3 (pl) * 2017-01-24 2023-06-12 I-Mab Biopharma Us Limited Przeciwciała anty-cd73 i ich zastosowania
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
EP4241807B1 (en) 2017-03-28 2025-02-19 Amgen Inc. Plunger rod and syringe assembly system
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3658203B2 (en) 2017-07-25 2025-10-01 Amgen Inc. Drug delivery device with gear module and related method of assembly
KR102577670B1 (ko) 2017-08-01 2023-09-12 암젠 인크 샘플의 실시간 글리칸 분석을 수행하기 위한 시스템 및 방법
WO2019028187A1 (en) 2017-08-01 2019-02-07 Amgen Inc. SYSTEMS AND METHODS FOR REAL-TIME PREPARATION OF A POLYPEPTIDE SAMPLE FOR MASS SPECTROMETRY ANALYSIS
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
WO2019178280A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
TW202529830A (zh) 2018-10-05 2025-08-01 美商安進公司 具有劑量指示器之藥物遞送裝置
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US12000775B2 (en) 2018-12-14 2024-06-04 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
WO2020168156A1 (en) 2019-02-14 2020-08-20 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
US12493019B2 (en) 2019-02-20 2025-12-09 Amgen Inc. Methods of determining protein stability
JP7570341B2 (ja) 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
EP3948242A1 (en) 2019-03-27 2022-02-09 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CN116751295A (zh) 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
EP4517327A3 (en) 2019-06-05 2025-05-07 Amgen Inc. Methods of identifying attributes of therapeutic proteins
CA3147044A1 (en) 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
IL292437A (en) 2019-10-28 2022-06-01 Medimmune Ltd Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AU2021219839A1 (en) 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
JP2023513833A (ja) 2020-02-18 2023-04-03 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023003164A (es) 2020-09-18 2023-05-04 Amgen Inc Metodos de procesamiento de una muestra para analisis de mapeo de peptidos.
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
MX2023005320A (es) 2020-11-05 2023-05-19 Amgen Inc Materiales y metodos para el procesamiento de proteinas.
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
KR20230140571A (ko) * 2021-02-04 2023-10-06 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 흉선 기질 림포포이에틴을 특이적으로 인식하는 항체 및 이의 용도
IL307439A (en) 2021-04-23 2023-12-01 Amgen Inc Different anti-TSLP antibodies
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
AU2022285961A1 (en) * 2021-05-30 2023-12-14 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
CA3237662A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
IL313679A (en) * 2021-12-24 2024-08-01 Inmagene Pte Ltd Novel anti-tslp antibodies
MX2024010773A (es) * 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118772266B (zh) * 2022-10-21 2025-06-17 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
CN120659807A (zh) * 2023-02-23 2025-09-16 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
TW202509066A (zh) 2023-05-18 2025-03-01 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2024264003A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
WO2024264002A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and tslpr and methods of use
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
TW202530266A (zh) * 2023-10-12 2025-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ＩＬ－４Ｒα抗體及其用途
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2033082A1 (en) 1989-06-15 1990-12-16 Linda S. Park Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1897949B1 (en) 1998-09-21 2014-11-12 Merck Sharp & Dohme Corp. Human interleukin-B50. Therapeutic uses
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
IL143034A0 (en) * 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
AU2001271624A1 (en) 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
DK1417231T3 (da) * 2001-07-23 2013-07-22 Immunex Corp Modificeret human thymisk stromal lymphopoietin
PT2311869E (pt) * 2002-02-01 2013-03-04 Merck Sharp & Dohme Utilização de reagentes relacionados com citoquinas de mamíferos
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
AU2004257781B2 (en) 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
AU2005307831A1 (en) * 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
EP1981912A2 (en) 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP2205635A1 (en) 2010-07-14
PH12017501025B1 (en) 2022-10-26
US8163284B2 (en) 2012-04-24
CA2698382A1 (en) 2009-03-19
IL204069A (en) 2017-03-30
HUE028361T2 (en) 2016-12-28
IL250900A0 (en) 2017-04-30
CY2022036I1 (el) 2023-01-05
AU2008300028A1 (en) 2009-03-19
HK1145843A1 (zh) 2011-05-06
TW201412774A (zh) 2014-04-01
LTC2205635I2 (cg-RX-API-DMAC7.html) 2025-10-27
RS54950B1 (sr) 2016-11-30
TW200918554A (en) 2009-05-01
FR22C1059I1 (fr) 2023-02-03
JP5956716B2 (ja) 2016-07-27
CN104231081A (zh) 2014-12-24
ZA201001895B (en) 2011-02-23
EP3524622A1 (en) 2019-08-14
PE20140232A1 (es) 2014-02-28
US10287348B2 (en) 2019-05-14
JP2017110011A (ja) 2017-06-22
PH12017501025A1 (en) 2018-01-29
HRP20160638T1 (hr) 2016-07-01
CL2012003245A1 (es) 2013-03-22
AU2008300028B2 (en) 2014-12-18
US9284372B2 (en) 2016-03-15
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
EP2703414A1 (en) 2014-03-05
EP2205635B1 (en) 2016-05-25
JP2020058365A (ja) 2020-04-16
SI2205635T1 (sl) 2016-09-30
CA2698382C (en) 2015-07-14
EA201590631A1 (ru) 2016-03-31
JP2024161358A (ja) 2024-11-19
SG10201506251YA (en) 2015-11-27
KR20140141666A (ko) 2014-12-10
LUC00289I2 (cg-RX-API-DMAC7.html) 2025-05-12
KR101597371B1 (ko) 2016-02-26
SG178781A1 (en) 2012-03-29
PE20110668A1 (es) 2011-10-01
FR22C1059I2 (fr) 2023-12-22
JP2023065375A (ja) 2023-05-12
US7982016B2 (en) 2011-07-19
US20120190829A1 (en) 2012-07-26
JP2010538608A (ja) 2010-12-16
MX2010002590A (es) 2010-03-26
HUS2200051I1 (hu) 2022-12-28
US20200071393A1 (en) 2020-03-05
JP2019038843A (ja) 2019-03-14
JP2021191758A (ja) 2021-12-16
CN104231081B (zh) 2022-01-11
TWI449709B (zh) 2014-08-21
ES2581229T3 (es) 2016-09-02
JP2015091820A (ja) 2015-05-14
CY2022036I2 (el) 2023-03-24
LT2205635T (lt) 2016-09-26
AR068508A1 (es) 2009-11-18
EA022796B1 (ru) 2016-03-31
CY1117702T1 (el) 2017-05-17
CN101809035A (zh) 2010-08-18
CL2008002668A1 (es) 2009-08-14
CR20150095A (es) 2015-04-06
KR20100067660A (ko) 2010-06-21
CN101809035B (zh) 2014-07-09
EA201000471A1 (ru) 2010-10-29
US20110274687A1 (en) 2011-11-10
NL301207I1 (nl) 2022-12-21
LTPA2022016I1 (cg-RX-API-DMAC7.html) 2023-01-10
NO2022055I1 (no) 2022-12-09
WO2009035577A1 (en) 2009-03-19
US20250154241A1 (en) 2025-05-15
NL301207I2 (nl) 2023-02-02
MY150242A (en) 2013-12-31
PL2205635T3 (pl) 2016-12-30
DK2205635T3 (en) 2016-07-18
JO3351B1 (ar) 2019-03-13
US20090238823A1 (en) 2009-09-24
NZ583933A (en) 2012-07-27
IL265854A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
CR11319A (es) Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica
CR20140585A (es) Proteinas de union a antigeno st2
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
GT200600186A (es) Agentes de unión
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CR20130128A (es) Nuevas proteínas de unión a antígenos
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
PL2270045T3 (pl) Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
EA201790757A1 (ru) Связывающие антиген cd27l белки
UY33319A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
BR112013027420A2 (pt) "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".
AR077630A1 (es) Polipeptidos y metodo de tratamiento
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
EA201390453A1 (ru) Человеческие анти-тау антитела
CR20110035A (es) Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
AR110159A2 (es) Anticuerpo humano anti-tslp (linfopoyetina estromal tímica), y su empleo en el tratamiento de una afección inflamatoria relacionada con la tslp